Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Studies indicate that there is a very low likelihood that people with HIV have preexisting resistance to the medication.
The integrase inhibitor–based HIV regimen was compared with dolutegravir-based regimens.
Genetic sequencing indicated that three samples from 1983 to 2001 were all part of a newly established subtype L of group M of the virus.
Newer drug classes are tied to a higher risk of weight gain, which is more likely to occur among Black women in particular.
The authors of the largest study to date to analyze condoms’ failure rate are pushing the FDA to finally approve them for anal sex use.
Factors associated with a higher risk of impairment include depression, poor adherence to antiretrovirals and opportunistic infections.
The rollout of antiretroviral treatment in this hard-hit region has apparently not lowered this group’s risk of acquiring HIV.
The first study of PrEP awareness and use among transgender men found that a majority are at risk for HIV.
People who start treatment within nine days, compared with more than 90, may be less likely to be in medical care one year later.
This finding raises concerns that staying off antiretrovirals may raise the risk of more serious cardiovascular problems.
Last year, the federal agency invested nearly $300 million in the search for HIV cure therapies.
However, serious kidney problems and bone fractures were rare among people taking either Descovy or Truvada for HIV prevention.
Foreign-born Latino men who have sex with men apparently have a lower rate of sex protected by PrEP, condoms or both.
Keeping people with HIV in consistent care and on treatment for the virus is vital to ensure they benefit from an undetectable viral load.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.